Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
Sanofi to receive a 12-month right of first negotiation (ROFN) to explore collaboration opportunities spanning multiple indications, including…